Additionally, direct CRISPR/Cas9 knockout of the PRLR in HR+ and HER2-E breast cancer cells caused dedifferentiation/aberrant differentiation, loss of linage specificity and led to enhanced tumorigenic and metastatic phenotypes [51]. This evidence concerns the gene ERBB2 and breast cancer.